Posted on

Myonexus Therapeutics is a clinical stage gene therapy company developing first ever treatments for Limb-girdle muscular dystrophy (LGMD) types 2D, 2B, 2E, 2L, and 2C based on research at Nationwide Children?s Hospital, a leader in muscular dystrophy gene therapy discovery and translational research. Acquired by Sarepta Therapeutics.